High-precision two-compartment open models with central elimination for parent compounds and active metabolites. Formulations include immediate release bolus deposition, enteric-delayed biphasic delivery, and zero-order osmotic release oral systems (OROS).
Competitive Hill-Langmuir receptor occupancy modeling at active biophase effect sites across ten primary biological pathways: GABAergic, serotonergic, dopaminergic, noradrenergic, glutamatergic, opioidergic and histaminergic, endocannabinoid, cardiovascular and hemodynamic, hemostatic and coagulation, and metabolic and endocrine pathways.
Clinical reasoning engine evaluating dynamic metabolic interactions across Cytochrome P450, UGT, and Phase II conjugation pathways. Continuous physiological scaling for renal function across KDIGO eGFR stages (15 to 130 mL/min/1.73m2), hepatic clearance and portosystemic shunting (Child-Pugh classes A, B, and C), gestational trimesters and lactation, severe thermal burn ICU resuscitation, onco-geriatric sarcopenia, G6PD deficiency, sickle cell disease, and target-mediated drug disposition (TMDD) for monoclonal antibodies.
Validated clinical coverage across psychiatric, neurological, cardiovascular, analgesic, anti-infective, oncology, immunology, and metabolic therapeutic classes: antidepressants, antipsychotics, mood stabilizers, anticonvulsants, anxiolytics, analgesics, anticoagulants, anti-infectives, monoclonal antibodies, and supportive care.